In addition, tumor specificity may remain a challenge, because in some entities, the maximum tolerated doses (MTD) of PARP inhibitors with RT and especially CRT can be severely reduced as compared to their use as monotherapy [51, 52]. This evidence concerns the gene PARP1 and neoplasm.